Publications by authors named "Arthur Joseph Asirvatham"
SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
J Assoc Physicians India
December 2024
For decades, achieving glycemic control, target blood pressure, and renin-angiotensin-aldosterone system (RAAS) blockade remained to be the therapeutic interventions for retarding diabetic kidney disease (DKD) progression. The management of DKD showed major transformation when SGLT2 inhibitors were recommended to reduce the risk of progressive deterioration in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), and renal death following results of CREDENCE and DAPA-CKD trials. Despite currently available therapeutic approaches, the risk of cardiac death, progression to ESRD, and requirement of renal replacement therapy remains high.
View Article and Find Full Text PDFArticle Synopsis
- - This study evaluated the willingness to pay (WTP) for biphasic insulin aspart 30/70 (BIAsp 30) among patients with type 2 diabetes in India who had previously used biphasic human insulin.
- - After 12 weeks of treatment, a significant 96.4% of patients expressed their willingness to pay for BIAsp 30, with noticeable improvements in treatment and device satisfaction.
- - Patients were willing to spend various amounts for benefits such as better glycemic control, device upgrades, and to avoid severe hypoglycemic episodes, highlighting their value placed on insulin treatment improvements.
Gene rs13266634 C/T Polymorphism in Children with Type 1 Diabetes in Tamil Nadu, India.
J Clin Res Pediatr Endocrinol
February 2019
Objective: Zinc transporter 8 (ZnT8) is a multi-transmembrane protein situated in the insulin secretory granule of the islets of β-cells and is identified as a novel auto-antigen in type 1 diabetes (T1D). The gene coding for ZnT8, solute carrier family 30 member 8 () is located on chromosome 8q24.11.
View Article and Find Full Text PDF